Last reviewed 2026-06-10 · How we verify

Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen — Treatment Landscape & Competitive Intelligence

Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent re

Marketed treatment landscape

Approved drugs treating Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer Inc. · 1 drug in Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen:

• Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen treatment updates — RSS
• Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen treatment updates — Atom
• Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen treatment updates — JSON

Cite this brief

Drug Landscape (2026). Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-third-dose-administered-at-least-2-months-after-either-the-second-dose-of-a-2-dose-series-or-the-first-dose-of-a-single-dose-regimen. Accessed 2026-06-10.

Related

• Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing